Temozolomide
Small molecule targets AGT, MGMT via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Kizfizo | — | 2025-05-02 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | TEMODAR | — | 2003-03-11 – 2023-09-14 | fda.gov ↗ |
| Approved | US (FDA) | TEMODAR | — | 1999-08-11 | fda.gov ↗ |
| Approved | EU (EMA) | Temodal | — | 1999-01-26 | europa.eu ↗ |
Trials 654 · started per year
Also used as a comparator or background therapy in 335 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06831526 Background | Nov 2025 → Feb 2029 expected | glioblastoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT06072586 Background | Oct 2023 → Dec 2026 expected | glioblastoma | St. Joseph's Hospital and Medical Center, Phoenix | Recruiting | No outcome recorded |
| Phase 0 | NCT05634707 Comparator | Aug 2023 → Dec 2026 expected | malignant glioma, primary brain neoplasm | Duke University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05589961 Background | Oct 2022 → Jul 2024 | glioblastoma | The Second Hospital of Hebei Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03554707 Background | Jun 2022 | central nervous system cancer | SynerGene Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 0 | NCT04614909 Background | Jan 2021 → Jul 2023 | adult glioblastoma | Nader Sanai | Completed | No outcome recorded |
| Phase 0 | NCT02970448 Background | Aug 2017 → Nov 2023 | malignant glioma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03122197 Background | May 2017 → Sep 2027 expected | brain neoplasm | University of Cincinnati | Recruiting | No outcome recorded |
| Phase 0 | NCT02507232 Comparator | Apr 2017 → Jul 2020 | low grade glioma | Santosh Kesari | Terminated | No outcome recorded |
| Phase 0 | NCT01907165 Background | Oct 2013 → Nov 2016 | glioblastoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 187 trials | ||||||
| Phase 1 | NCT07223034 Background | Oct 2025 → Oct 2027 expected | IDH-wildtype glioblastoma, diffuse astrocytoma, diffuse glioma, H3 G34 mutant, diffuse midline glioma, H3 K27-altered +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06995872 Background | Oct 2025 → Jun 2028 expected | neuroblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT07027748 Background | Jun 2025 → Jul 2027 expected | neuroblastoma | Steven DuBois, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06428045 Background | Apr 2025 → Apr 2029 expected | malignant glioma | University of Miami | Recruiting | No outcome recorded |
| Phase 1 | NCT06934889 Background | Apr 2025 → Apr 2028 expected | gliosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05400603 Background | Nov 2023 → Dec 2026 expected | neuroblastoma, osteosarcoma | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT06006273 Background | Aug 2023 → Dec 2026 expected | refractory malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05030298 Background | May 2023 → Sep 2027 expected | malignant glioma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT05413304 Background | Apr 2023 → Oct 2025 overdue | glioma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04900792 Background | Feb 2023 → May 2025 overdue | glioblastoma | Bryan Allen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04525014 Background | Jan 2023 → Jul 2024 | brain cancer, childhood malignant neoplasm | EpicentRx, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04385173 Background | Dec 2022 → Mar 2024 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05421897 Background | Nov 2022 → Jan 2026 overdue | neuroblastoma | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05769660 Background | Nov 2022 → Nov 2026 expected | glioblastoma | BeyondBio Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07635173 Background | Sep 2022 → Apr 2024 | glioblastoma | Shenzhen Zhenxing Medical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05236036 Background | Aug 2022 → Jan 2026 overdue | IDH-wildtype glioblastoma, astrocytoma (excluding glioblastoma) | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05190315 Background | Jan 2022 → Apr 2023 | glioblastoma | Mohammed Milhem | Completed | No outcome recorded |
| Phase 1 | NCT06760117 Background | Jan 2022 → Jun 2025 overdue | childhood malignant neoplasm | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT04337177 Background | Oct 2021 → Jun 2026 overdue | Ewing sarcoma, hepatoblastoma, medulloblastoma, neuroblastoma +1 | Valent Technologies, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04968366 Background | Jul 2021 → Apr 2024 | brain glioblastoma | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04555577 Background | Sep 2020 → Dec 2027 expected | gliosarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04477200 Background | Aug 2020 → Jan 2025 overdue | astrocytoma (excluding glioblastoma), gliosarcoma | University of Michigan Rogel Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04324840 Background | Jul 2020 → Jul 2024 | glioblastoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04216329 Background | Jul 2020 → Sep 2023 overdue | gliosarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04091503 Comparator | Dec 2019 → Sep 2022 | brain astrocytoma, gliosarcoma | Center Trials & Treatment Europe | Completed | No outcome recorded |
| Phase 1 | NCT03705351 Background | Dec 2019 → Feb 2021 | brain cancer, glioblastoma | Providence Health & Services | Terminated | No outcome recorded |
| Phase 1 | NCT03687034 Background | Jun → Sep 2019 | glioblastoma | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03528642 Background | May 2019 → Sep 2026 expected | astrocytoma, IDH-mutant, grade 2, astrocytoma, IDH-mutant, grade 3 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03715933 Background | Oct 2018 → Dec 2028 expected | Ewing sarcoma, colorectal adenocarcinoma | Inhibrx Biosciences, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT03299309 Background | Jun 2018 → Apr 2023 overdue | brain cancer, malignant glioma, medulloblastoma | Daniel Landi | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03514069 Background | Jun 2018 → Aug 2021 | glioblastoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03451799 Background | Apr 2018 → Sep 2021 | glioblastoma | Jethro Hu | Completed | No outcome recorded |
| Phase 1 | NCT03246113 Background | Mar 2018 → May 2019 | glioblastoma | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03426891 Background | Mar 2018 → Oct 2021 | brain neoplasm, glioblastoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT03344250 Background | Mar 2018 → Dec 2021 | glioblastoma | University of Virginia | Completed | No outcome recorded |
| Phase 1 | NCT03576612 Background | Feb 2018 → Jun 2023 | malignant glioma | Candel Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03323034 Background | Jan 2018 → Sep 2021 | central nervous system neoplasm, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT02880410 Background | Aug 2017 → Sep 2018 | glioblastoma | Monteris Medical | Terminated | No outcome recorded |
| Phase 1 | NCT02975882 Background | Aug 2017 → Mar 2022 | central nervous system cancer, childhood neoplasm, refractory malignant neoplasm, secondary malignant neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT02871843 Background | Feb 2017 → Oct 2019 | anaplastic oligodendroglioma, glioblastoma, oligodendroglioma | EpicentRx, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02903069 Background | Aug 2016 → Jan 2021 | glioblastoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02378532 Background | Aug 2016 → Jan 2019 | glioblastoma | Maastricht Radiation Oncology | Completed | No outcome recorded |
| Phase 1 | NCT02193347 Background | Jan 2016 → Feb 2020 | brain glioma, primary brain neoplasm | Katy Peters, MD, PhD | Completed | No outcome recorded |
| Phase 1 | NCT02510950 Background | Dec 2015 → Feb 2017 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT02502708 Background | Oct 2015 → Dec 2019 | diffuse intrinsic pontine glioma, ependymoma, gliosarcoma, medulloblastoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02530502 Background | Sep 2015 → May 2016 | adult glioblastoma | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT02311920 Background | Apr 2015 → Dec 2017 | gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02392793 Comparator | Mar 2015 → Feb 2019 | childhood malignant neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02337426 Background | Feb 2015 → Nov 2016 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 1 | NCT02254954 Background | Jan 2015 → Sep 2016 | glioblastoma | Actelion | Terminated | No outcome recorded |
| Phase 1 | NCT02272270 Background | Oct 2014 → Mar 2017 | glioma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02203526 Background | Aug 2014 → Sep 2026 expected | primary central nervous system lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02168270 Background | Jun 2014 → Aug 2015 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, gliosarcoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 1 | NCT01811992 Background | Apr 2014 → Feb 2019 | glioblastoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02010606 Background | Jan 2014 → Jan 2019 | astrocytoma (excluding glioblastoma), brain neoplasm, glioblastoma | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01849146 Background | Oct 2013 → Jul 2021 | glioblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01891747 Background | Jul 2013 → Jun 2015 | malignant glioma | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01800695 Background | Apr 2013 → Jun 2017 | glioblastoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01752491 Background | Apr 2013 → Nov 2015 | glioblastoma | Joseph J. Cullen, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT01409174 Background | Feb 2013 → May 2016 | melanoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01700569 Background | Jan 2013 → Dec 2019 | glioblastoma | Institut Cancerologie de l'Ouest | Terminated | No outcome recorded |
| Phase 1 | NCT01528046 Background | Sep 2012 → Sep 2019 | cancer, primary brain neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01480050 Background | May 2012 → Aug 2015 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT01576692 Background | Apr 2012 → Oct 2014 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01499251 Background | Jan 2012 → Jan 2016 | glioblastoma | Actelion | Terminated | No outcome recorded |
| Phase 1 | NCT01473901 Background | Dec 2011 → May 2017 | glioblastoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01269424 Comparator | Nov 2011 → Dec 2020 | glioblastoma | Stanton Gerson MD | Completed | No outcome recorded |
| Phase 1 | NCT01222221 Background | Jul 2010 → Feb 2015 | central nervous system neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT01141244 Background | Jun 2010 → Nov 2013 | childhood malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01119599 Background | May 2010 → Jun 2013 | acoustic neuroma, adult brain ependymoma, adult brainstem glioma, adult choroid plexus neoplasm +23 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01127178 Background | Mar 2010 → Feb 2011 | cancer | Eisai Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01076530 Background | Feb 2010 → Oct 2012 | atypical teratoid rhabdoid tumor, central nervous system teratoma, childhood brain stem glioma, childhood central nervous system germinoma +22 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00960063 Background | Nov 2009 → Dec 2010 | bone cancer, kidney neoplasm, neuroblastoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00895960 Background | May 2009 → Aug 2013 | brain disorder, glioblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00915694 Background | Apr 2009 → Jul 2011 | central nervous system neoplasm | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00768911 Background | Oct 2008 → Oct 2010 | glioblastoma | Adnexus, A Bristol-Myers Squibb R&D Company | Unknown | No outcome recorded |
| Phase 1 | NCT00786669 Background | Oct 2008 → Nov 2012 | cancer | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1 | NCT00704080 Background | Aug 2008 → Feb 2012 | glioblastoma, mixed glioma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00720564 Background | Apr 2008 → Feb 2009 | central nervous system neoplasm | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00516607 Background | Jul 2007 → Nov 2008 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 1 | NCT00387400 Background | Mar 2007 → Sep 2010 | central nervous system neoplasm | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1 | NCT00626015 Background | Mar 2007 → Feb 2013 | brain cancer | John Sampson | Completed | No outcome recorded |
| Phase 1 | NCT00390403 Background | Feb 2007 → Jun 2009 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00385853 Background | Sep 2006 → Sep 2011 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00083096 Background | Mar 2004 → Jun 2009 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 1 | NCT00049387 Background | Sep 2002 → Jun 2007 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02227901 Background | Sep 2002 → Jun 2007 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/259 trials | ||||||
| Phase 1/2 | NCT04373785 Background | Jan 2027 → Jul 2030 expected | glioblastoma | NeuGATE Theranostics | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06639607 Background | Aug 2026 → Aug 2031 | ependymoma, medulloblastoma | Washington University School of Medicine | Suspended | No outcome recorded |
| Phase 1/2 | NCT07346157 Background | Jul 2026 → Mar 2031 expected | childhood medulloblastoma | Sabine Mueller, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07562971 Background | May 2026 → Nov 2030 expected | diffuse midline glioma, H3 K27-altered | UMC Utrecht | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07389278 Background | Mar 2026 → Jun 2032 expected | diffuse glioma, H3 G34 mutant, diffuse midline glioma, H3 K27M-mutant, glioblastoma | Sabine Mueller, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06709495 Background | Jan 2025 → Nov 2028 expected | Ewing sarcoma, desmoplastic small round cell tumor, osteosarcoma, rhabdomyosarcoma | David S Shulman, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06478212 Background | Jan 2025 → Nov 2027 expected | glioma | Servier | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06504381 Background | Jan 2025 → Jan 2028 expected | glioblastoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07334301 Background | Nov 2024 → Dec 2030 expected | neuroblastoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04890093 Background | Oct 2024 → Dec 2026 | Ewing sarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1/2 | NCT06541262 Background | Oct 2024 → Nov 2030 expected | Ewing sarcoma, liposarcoma, neuroblastoma, osteosarcoma +1 | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06556199 Background | Aug 2024 → Aug 2026 overdue | primary central nervous system lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03529448 Background | Aug 2023 → Nov 2025 | glioblastoma | Grupo Español de Investigación en Neurooncología | Completed | No outcome recorded |
| Phase 1/2 | NCT06012695 Background | Aug 2023 → May 2028 expected | brain cancer | Novelwise Pharmaceutical Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05765812 Background | May 2023 → Sep 2028 expected | IDH-wildtype glioblastoma, grade III glioma | Debiopharm International SA | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05432804 Background | Mar 2023 → Jun 2027 expected | IDH-wildtype glioblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05664464 Background | Jan 2023 → Jun 2026 overdue | glioblastoma | University of Zurich | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04881032 Background | Mar 2022 → Sep 2025 overdue | glioblastoma | Centre Jean Perrin | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04019262 Comparator | Dec 2021 → Dec 2026 expected | glioblastoma | John Flickinger | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04911621 Background | Sep 2021 → Aug 2025 | diffuse intrinsic pontine glioma, high grade astrocytic tumor | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1/2 | NCT05027386 Background | Aug 2021 → Feb 2026 overdue | neuroblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04851834 Background | Aug 2021 → Nov 2022 | malignant glioma, urothelial carcinoma | Xennials Therapeutics Australia Pty Ltd | Terminated | No outcome recorded |
| Phase 1/2 | NCT05004116 Background | Aug 2021 → Aug 2028 expected | metastatic neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04901702 Comparator | Jun 2021 → Dec 2026 expected | Ewing sarcoma, Wilms tumor, hepatoblastoma, malignant germ cell tumor +5 | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04443010 Background | Jan 2021 → Oct 2026 expected | glioblastoma | Philogen S.p.A. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04388033 Background | Dec 2020 → Dec 2022 | glioblastoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04625907 Comparator | Sep 2020 → Jun 2030 expected | rhabdomyosarcoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04478279 Background | Jul 2020 → Dec 2026 expected | brain cancer, breast cancer, glioblastoma, metastatic melanoma +1 | Sapience Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04121455 Comparator | Sep 2019 → Dec 2028 expected | glioblastoma | TME Pharma AG | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03607643 Background | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03687957 Background | Jan 2019 → Feb 2023 overdue | glioma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02655601 Background | Sep 2018 → Aug 2023 | anaplastic astrocytoma, glioblastoma | BioMimetix JV, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03491683 Background | May 2018 → Dec 2026 expected | glioblastoma | Inovio Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03234595 Background | Nov 2017 → Apr 2023 | glioblastoma | Everfront Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02715609 Background | Jun 2016 → May 2024 | glioblastoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT02649582 Background | Dec 2015 → Jul 2027 expected | brain glioblastoma | University Hospital, Antwerp | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02364206 Background | Jun 2015 → Aug 2019 | adult glioblastoma | Centre Jean Perrin | Completed | No outcome recorded |
| Phase 1/2 | NCT02315534 Background | Mar 2015 → Oct 2018 | glioblastoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01977677 Background | Nov 2014 → Nov 2017 | adult glioblastoma, adult medulloblastoma, adult pineoblastoma, ependymoblastoma +4 | Lawrence Recht | Completed | No outcome recorded |
| Phase 1/2 | NCT01837862 Background | Oct 2013 → Apr 2024 | anaplastic astrocytoma, diffuse intrinsic pontine glioma, gliosarcoma, optic nerve glioma +2 | Julie Krystal | Completed | No outcome recorded |
| Phase 1/2 | NCT02046187 Background | Oct 2013 → Feb 2017 | glioblastoma | St. Joseph's Hospital and Medical Center, Phoenix | Terminated | No outcome recorded |
| Phase 1/2 | NCT02025881 Background | Sep 2013 → Oct 2020 | medulloblastoma | Gustave Roussy, Cancer Campus, Grand Paris | Terminated | No outcome recorded |
| Phase 1/2 | NCT01790503 Background | Jul 2013 → Nov 2017 | glioblastoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/2 | NCT02085304 Background | May 2013 → May 2015 | glioblastoma | St. Joseph's Hospital and Medical Center, Phoenix | Terminated | No outcome recorded |
| Phase 1/2 | NCT01618136 Comparator | Jan 2012 → Jul 2015 | indolent B-cell non-Hodgkin lymphoma, melanoma, ovarian carcinoma, triple-negative breast carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01505608 Background | Dec 2011 → Dec 2014 | neuroblastoma | Giselle Sholler | Terminated | No outcome recorded |
| Phase 1/2 | NCT01220271 Background | Apr 2011 → Aug 2015 | glioma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01181193 Background | Mar 2011 → Mar 2013 | glioblastoma | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01062399 Background | Dec 2010 → Jun 2016 | central nervous system neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00939991 Background | Oct 2009 → Jan 2012 | brain neoplasm, glioblastoma | Katy Peters | Completed | No outcome recorded |
| Phase 1/2 | NCT00869401 Background | Jun 2009 → Oct 2014 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00553150 Background | Mar 2009 → Jan 2012 | central nervous system neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT00724841 Background | Jun → Jul 2008 | metastatic melanoma | Gemin X | Terminated | No outcome recorded |
| Phase 1/2 | NCT00662506 Background | Apr 2008 → Apr 2014 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00609011 Background | Mar 2008 → Aug 2009 | metastatic melanoma | Myrexis Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00486603 Background | Oct 2007 → Jun 2013 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/2 | NCT00441142 Background | May 2007 → Aug 2013 | gliosarcoma | Patrick Y. Wen, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00394628 Background | Oct 2006 → ? | glioblastoma | Novacea | Unknown | No outcome recorded |
| Phase 1/2 | NCT00305864 Background | Feb 2006 → Feb 2011 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2116 trials | ||||||
| Phase 2 | NCT01777919 Background | Jan 2027 → Jan 2029 expected | glioblastoma | Olympion Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07707973 Background | Jul 2026 → Jan 2028 expected | malignant glioma | Tianjin First Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07326566 Comparator | May 2026 → Nov 2028 expected | brain cancer, glioblastoma | Black Diamond Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07406724 Comparator | Feb 2026 → Dec 2027 expected | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07400302 Background | Feb 2026 → Sep 2029 expected | mucosal melanoma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 2/313 trials | ||||||
| Phase 2/3 | NCT07349693 Background | Nov 2026 → Dec 2028 expected | IDH-wildtype glioblastoma | Everfront Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07605364 Background | Jun 2026 → Sep 2029 expected | glioblastoma | Alliance for Clinical Trials in Oncology | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07549321 Background | Mar 2026 → Mar 2031 expected | neuroblastoma | Renaissance Pharma Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06624644 Comparator | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04396860 Comparator | Sep 2020 → Jan 2023 | gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT04105374 Background | Jan 2020 → Nov 2025 | anaplastic astrocytoma, glioblastoma, oligodendroglioma | NRG Oncology | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04250922 Background | Dec 2019 → Jan 2026 overdue | glioblastoma | Laminar Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03970447 Comparator | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03008148 Background | Oct 2018 → Apr 2025 | glioblastoma | Johnpro Biotech, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT06105619 Comparator | Oct 2018 → Apr 2023 overdue | glioblastoma | Beijing Pearl Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03548571 Comparator | Apr 2018 → Dec 2025 | glioblastoma | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02678975 Background | Jan 2017 → Jan 2021 | glioblastoma | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02414165 Comparator | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | No outcome recorded |
| Phase 344 trials | ||||||
| Phase 3 | NCT06448286 Background | Dec 2026 → Dec 2030 expected | glioblastoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07215910 Background | Jul 2026 → May 2033 expected | astrocytoma, IDH-mutant, grade 3 | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT07104032 Comparator | Jun 2026 → Dec 2027 expected | primary central nervous system lymphoma | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07452458 Background | Jun 2026 → Jan 2030 expected | IDH-wildtype glioblastoma | NRG Oncology | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07004075 Comparator | Jun 2025 → Apr 2027 expected | childhood low-grade glioma, diffuse low-grade glioma, MAPK pathway–altered | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06556563 Background | Feb 2025 → Apr 2029 expected | glioblastoma | NovoCure Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06477939 Background | Jan 2025 → Dec 2032 expected | glioblastoma | Institut de cancérologie Strasbourg Europe | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06264180 Comparator | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06388733 Comparator | Jun 2024 → Dec 2027 expected | glioblastoma, primary brain neoplasm | Ivy Brain Tumor Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06346067 Comparator | Apr 2024 → Apr 2028 expected | melanoma | Erasca, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06172296 Background | Apr 2024 → Dec 2029 expected | neuroblastoma, nodular ganglioneuroblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06330337 Background | Apr 2024 → Dec 2026 expected | glioma | The Third Affiliated hospital of Zhejiang Chinese Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05902169 Comparator | Jan 2024 → Jan 2028 expected | glioblastoma | CarThera | Recruiting | No outcome recorded |
| Phase 3 | NCT06008106 Comparator | Nov 2023 → Sep 2027 expected | melanoma | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05647954 Comparator | Dec 2022 → Dec 2024 | neuroendocrine neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05326464 Background | Oct 2022 → Feb 2025 | glioblastoma | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT05271240 Comparator | Apr 2022 → Apr 2027 expected | IDH-wildtype glioblastoma, adult glioblastoma, brain cancer | Northwell Health | Recruiting | No outcome recorded |
| Phase 3 | NCT04919226 Comparator | Dec 2021 → Jun 2027 expected | neuroendocrine neoplasm | ITM Solucin GmbH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03776071 Comparator | Dec 2020 → Feb 2024 | glioblastoma | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 3 | NCT03495921 Background | Aug 2018 → Jan 2022 | Ewing sarcoma, bone neoplasm, connective and soft tissue neoplasm | Gradalis, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03419403 Background | Jul 2018 → Sep 2019 | glioblastoma | AbbVie | Terminated | No outcome recorded |
| Phase 3 | NCT03345095 Background | Jul 2018 → Aug 2022 | glioblastoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT03393000 Background | Jan 2018 → Nov 2020 | glioblastoma | Diffusion Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 3 | NCT03149575 Comparator | Oct 2017 → May 2019 | brain cancer, glioblastoma | DelMar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02667587 Background | May 2016 → Dec 2020 | brain neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02617589 Comparator | Mar 2016 → Jan 2019 | brain cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02288897 Comparator | Apr 2015 → Apr 2019 | cutaneous melanoma | Provectus Biopharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02573324 Background | Jan 2015 → Apr 2022 | gliosarcoma | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT01830101 Background | Feb 2014 → May 2015 | glioblastoma | AHS Cancer Control Alberta | Withdrawn | No outcome recorded |
| Phase 3 | NCT01260103 Comparator | Dec 2011 → Dec 2016 | optic nerve glioma | Burzynski Research Institute | Withdrawn | No outcome recorded |
| Phase 3 | NCT01480479 Background | Nov 2011 → Nov 2016 | giant cell glioblastoma, gliosarcoma, mixed astrocytoma-ependymoma-oligodendroglioma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT05718466 Background | Nov 2010 → Dec 2016 | glioblastoma | Henry Ford Health System | Completed | No outcome recorded |
| Phase 3 | NCT01149109 Comparator | Oct 2010 → Apr 2017 | glioblastoma | University Hospital, Bonn | Completed | No outcome recorded |
| Phase 3 | NCT00943826 Background | Jun 2009 → Feb 2013 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00916409 Comparator | Jun 2009 → Dec 2016 | glioblastoma | NovoCure Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00884741 Background | Apr 2009 → Mar 2013 | gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00761280 Comparator | Dec 2008 → Feb 2012 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Terminated | No outcome recorded |
| Phase 3 | NCT00689221 Background | Sep 2008 → Nov 2012 | glioblastoma | EMD Serono | Completed | No outcome recorded |
| Phase 3 | NCT00615186 Comparator | Jun 2008 → Aug 2013 | glioblastoma | Bradmer Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00626990 Comparator | Dec 2007 → Sep 2018 overdue | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00482677 Comparator | Nov 2007 → Mar 2016 | central nervous system neoplasm | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00395070 Comparator | Oct 2006 → Mar 2012 | metastatic melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00257205 Comparator | Mar 2006 → Aug 2010 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06625047 Background | Oct 2024 → Nov 2025 | IDH-mutant and 1p/19q-codeleted oligodendroglioma, astrocytoma (excluding glioblastoma), glioblastoma | Mayo Clinic | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06271421 Comparator | Jan 2024 → Feb 2027 expected | glioblastoma | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
| — | NCT03217097 Comparator | Oct 2018 → Jan 2022 | neuroendocrine neoplasm | Hospices Civils de Lyon | Completed | No outcome recorded |
| — | NCT03168919 Background | Oct 2016 → Jun 2018 | glioma | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT02015728 Background | Dec 2013 → Nov 2016 | brain cancer | Seattle Children's Hospital | Unknown | No outcome recorded |
| — | NCT00756106 Background | Jul 2008 → Feb 2012 | central nervous system neoplasm | Massachusetts General Hospital | Terminated | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-08-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceuticals and Perrigo Company Announce the U.S. Launch of Generic Temozolomide tevapharm.com ↗ |
| 2010-03-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update on Generic Temodar® tevapharm.com ↗ |
| 2010-01-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives Favorable Court Decision Regarding Generic Temodar® tevapharm.com ↗ |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 1,041 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | temozolomide | “The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the...” NCT04250922 ↗974“Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Carboplatin; * Irinotecan; * Etoposide; *...” NCT03632135 ↗ “This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide...” NCT01605162 ↗ “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗ “The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent...” PMID 25480497 ↗ Dec 2014 “Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous...” NCT02399189 ↗ “The "alkylating-based" group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or...” NCT03217097 ↗ “A Randomized, Controlled, Open-label, Multicenter Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of KH617 in Combination With Temozolomide Versus Investigator's...” NCT07138001 ↗ “Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1...” NCT04532229 ↗ “Temozolomide 75mg/m2 orally once daily (usually administered the night preceding each radiation session) starting the evening before the first radiation session over a period...” NCT03393000 ↗ “Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no...” NCT06477939 ↗ “the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.” NCT06594432 ↗ “Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)” NCT03964090 ↗ “The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.” NCT06161974 ↗ “SI-053 is a novel powder formulation containing temozolomide (TMZ), an alkylating chemotherapy agent, in an excipient which forms a viscous gel upon reconstitution in water.” NCT04967690 ↗ “Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)” NCT02203526 ↗ “temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days.” NCT01310868 ↗ “PURPOSE: To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma.” PMID 15234047 ↗ Jul 2004 “Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.” PMID 29683790 ↗ Apr 2018 “Temozolomide is administered orally once daily at bedtime on an empty stomach at a dose of 150 mg/m² or 200 mg/m², as determined by the investigator” NCT07635173 ↗ “The chemotherapy that is being used in this study is called temozolomide (TMZ) which is the standard-of-care used to treat glioblastoma patients.” NCT05664243 ↗ “Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study.” NCT03234595 ↗ “RMT Regimen: Rituximab 375 mg/m² IV on Day 0; Methotrexate 3.5 g/m² IV on Day 1; Temozolomide 150 mg/m² orally once daily on Days 1-5.” NCT07350850 ↗ “Days 2-6: Temozolomide at 100 mg/m2 (cycles 1) and in 50 mg/m2 steps to 200 mg/m2 from cycle 2 on dependent on hematological toxicity” NCT05331521 ↗ “neoadjuvant immunotherapy(Toripalimab ) combine with radiotherapy and concurrent chemotherapy(Temozolomide) before Endoscopic Surgery” NCT07614828 ↗ “Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule” NCT06381726 ↗ “The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective.” NCT03396575 ↗ “All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；” NCT05512481 ↗ “For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.” NCT00613028 ↗ “FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po” NCT05274139 ↗ “Temozolomide is a chemotherapy drug that is designed to attach to the DNA of rapidly dividing cells (cancer cells).” NCT00515788 ↗ “Single-agent or combination chemotherapy regimens include dacarbazine, temozolomide, paclitaxel, and carboplatin.” NCT07406724 ↗ “in combination with Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors” NCT01618136 ↗ “Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma” NCT05789043 ↗ “In this study, the same chemotherapy (Temozolomide) normally given after radiation therapy for glioblastoma.” NCT07476794 ↗ “A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration.” NCT00991250 ↗ “Standard of care in 2016 comprises surgical resection, radiotherapy and chemotherapy (temozolomide).” PMID 28720549 ↗ Jul 2017 “Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.” NCT00610571 ↗ “Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week.” NCT06271421 ↗ “Temozolomide will be taken by mouth for five days in a row (Days 1, 2, 3, 4 and 5) of each cycle.” NCT00527761 ↗ “single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum” NCT05868707 ↗ “Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.” NCT06438614 ↗ “Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)” NCT00763750 ↗ “concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period” NCT06418113 ↗ “6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).” NCT07120984 ↗ “Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.” NCT01499251 ↗ “After enrollment, temozolomide 50mg/m2 was given orally for QD until progression” NCT05589961 ↗ “Both groups will continue to receive the standard therapy of oral Temozolomide.” NCT07225621 ↗ “Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy.” NCT02772094 ↗ “Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion.” NCT00616005 ↗ “Investigator's Choice Treatment：bevacizumab, temozolomide or hydroxyurea” NCT07613450 ↗ “dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d” NCT03660761 ↗ “temozolomide (TMZ), a DNA alkylating agent used to treat brain tumors.” PMID 32652442 ↗ Jul 2020 “Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os)” NCT03663725 ↗ “Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.” NCT06264180 ↗ “Temozolomide capsules were obtained locally by the Investigator” NCT01708174 ↗ “temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan” NCT01576692 ↗ “Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle.” NCT01567202 ↗ “Either irinotecan or temozolomide or carboplatin or etoposide” NCT05718466 ↗ “Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days.” NCT03299309 ↗ “Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;” NCT02025881 ↗ “Temozolomide administered on day 1 of treatment cycle” NCT00612989 ↗ “oral temozolomide 200 mg/m2 once a day, Day 10 to 14” NCT03079440 ↗ “Temozolomide at 75 mg/m2 per day from day 2 to day 6” NCT00249964 ↗ “with concurrent daily temozolomide (60 mg/m2 p.o.)” NCT01124240 ↗ “Temozolomide: 150mg-200mg/m2, qd, po, D10-D14, Q4W” NCT07357623 ↗ “radiotherapy (RT), temozolomide (TMZ), and Optune” NCT02903069 ↗ “then given temozolomide (150mg/m2 for 5 Days)” NCT04253873 ↗ “Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2)” NCT02727387 ↗ “temozolomide, fractionated radiochemotherapy” NCT03395587 ↗ “Temozolomide (PO) will be dosed at 150 mg” NCT03332355 ↗ “Radiosensitive therapy with Temozolomide” NCT02567539 ↗ “Temozolomide: 150 mg/m2 d1-5, i.v. Q3W;” NCT06041724 ↗ “Temozolomide, PO, D1 to D5, 150mg/m²/d” NCT03011528 ↗ “lomustine (CCNU), PCV or temozolomide” NCT02678975 ↗ “temozolomide:75mg/m2/d，d1-d21，PO，Q4W” NCT07698054 ↗ “IMP4297(senaparib) and temozolomide” NCT04434482 ↗ “receive RT and temozolomide (TMZ)” NCT06816927 ↗ “radiation and temozolomide (TMZ)” PMID 38263486 ↗ Jan 2024 “temozolomide 100 mg on days 1-5” NCT06445257 ↗ “Temodar (temozolomide [TMZ])” NCT02254954 ↗ “7. MGMT: Temozolomide” NCT02101385 ↗ “temozolomide (TMZ)” NCT01127178 ↗ “Drug: Temozolomide” NCT02511132 ↗ “Drug: Temozolomide” NCT00639262 ↗ “temozolomide (TMZ)” NCT04817254 ↗ “Drug: Temozolomide” NCT03204032 ↗ “Temozolomide” NCT03529448 ↗ “Temozolomide” NCT01478854 ↗ “Temozolomide” NCT05421897 ↗ |
| Known as | benzolamide | “Drug Therapy with Temozolomide (benzolamide) (Standard of Care)” NCT04209790 ↗ |
| Known as | Radiotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04866836 ↗ |
| Known as | RiMO-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05838729 ↗ |
| Known as | SCH 52365 | “Continuous Temozolomide (SCH 52365) in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer, Phase II” NCT00194766 ↗2“Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme” NCT00006358 ↗ “temozolomide (SCH 52365, Temodar (R))” NCT00005637 ↗ |
| Known as | Temodal | “Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas” NCT00003718 ↗4“only Temodal® capsules must be used to generate a temozolomide suspension” NCT03243461 ↗ |
| Known as | Temodar | “On March 15, 2005, the U.S. Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with...” PMID 16203762 ↗ Oct 200520“One currently used drug called Temozolomide (Temodar) has been shown to be active in human brain tumors but its actual central nervous system (CNS) penetration is unknown.” NCT01180816 ↗ “Temozolomide (Temodar) is an anti-cancer drug that works by interfering with the growth of cells (including cancer cells) by stopping their division.” NCT00590681 ↗ “Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas.” NCT00657267 ↗ “Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma” NCT00006025 ↗ “Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.” NCT01107522 ↗ “The product label for temozolomide (Temodar®) provides the following dosing information.” NCT03149575 ↗ “With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856)” NCT00005951 ↗ “Temodar® (temozolomide)” NCT00409383 ↗ “Temodar (Temozolomide)” NCT01067066 ↗ “Temodar (Temozolomide)” NCT06805305 ↗ “Temozolomide (temodar)” NCT00846430 ↗ “Temodar (Temozolomide)” NCT00508456 ↗ “Drug: Temodar” NCT00667953 ↗ |
| Known as | Temodar (R) | “temozolomide (SCH 52365, Temodar (R))” NCT00005637 ↗ |
| Known as | Temodar (temozolomide [TMZ]) | “Temodar (temozolomide [TMZ])” NCT02254954 ↗ |
| Known as | Temodar - Temozolomide | “Temodar - Temozolomide” NCT00610571 ↗5“Temodar - Temozolomide” NCT00613093 ↗ “Temodar (temozolomide)” NCT01186406 ↗ “Temodar (Temozolomide)” NCT00249964 ↗ “Temodar - Temozolomide” NCT00616005 ↗ “Temodar-Temozolomide” NCT00612638 ↗ |
| Known as | Temozolomid | “Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks” NCT00004106 ↗ |
| Known as | Temozolomide (Temodar) | “Temozolomide (Temodar)” NCT00939991 ↗ |
| Known as | Temozolomide (TMZ) | “Temozolomide (TMZ)” NCT06504381 ↗ |
| Known as | Temozolomide Injection | “Drug: Temozolomide Injection” NCT05512481 ↗ |
| Known as | Temozolomide is also known as Temodar | “Temozolomide is also known as Temodar” NCT00304200 ↗ |
| Known as | temozolomide, temodar/temodal | “temozolomide, temodar/temodal” NCT01113957 ↗ |
| Known as | TMZ | “PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ...” PMID 28011051 ↗ Nov 2016155“The European Organization for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT)...” PMID 21880994 ↗ Aug 2011 “PURPOSE: This pediatric phase I trial of O6-benzylguanine (O6BG) and temozolomide (TMZ) on a daily schedule for 5 days, every 28 days was performed to determine the...” PMID 16234526 ↗ Oct 2005 “To evaluate the clinical efficacy of adding temozolomide (TMZ) to preoperative capecitabine (CAP)-based chemoradiotherapy in patients with locally advanced rectal cancer (LARC)...” PMID 36376167 ↗ Nov 2022 “Adults with newly diagnosed uMGMT glioblastoma and Karnofsky performance status (KPS) ≥70 were randomly assigned to radiotherapy with either immunotherapy (ipi and nivo) or...” PMID 40779733 ↗ Aug 2025 “This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and...” PMID 19289491 ↗ Mar 2009 “This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide...” NCT01605162 ↗ “This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in...” NCT00643825 ↗ “BACKGROUND: Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients...” PMID 35419607 ↗ Jan 2023 “Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and...” PMID 29683790 ↗ Apr 2018 “This randomised phase II study evaluated the use of Temozolomide (TMZ) concomitant with 30 Gray (Gy) of Whole-brain irradiation (WBI) for 2 weeks without adjuvant TMZ vs. WBI...” PMID 22257825 ↗ Jan 2012 “Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1...” NCT04532229 ↗ “We conducted a phase I translational study to evaluate the toxicities and estimate the maximum tolerated dose (MTD) of laromustine when administered with temozolomide (TMZ) in...” PMID 20511167 ↗ Jun 2010 “Patients with glioblastoma multiforme (GBM) are profoundly immunosuppressed and may benefit from restoration of an antitumor immune response in combination with conventional...” PMID 21499132 ↗ May 2011 “This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to compare how well they work with or without bevacizumab in treating patients with newly...” NCT00884741 ↗ “We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a...” PMID 28472509 ↗ Oct 2017 “The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for...” PMID 24991840 ↗ May 2014 “TTFields (200 kHz) improved median progression-free survival (PFS) and median overall survival (OS) in patients with newly diagnosed GBM (ndGBM) when added concomitantly to...” PMID 34692470 ↗ Sep 2021 “Several agents, such as high-dose MTX, temozolomide (TMZ), rituximab, with a reported activity in PCNSL and acceptable safety profile, as single agent or combined, are good...” NCT02313389 ↗ “This study investigated whether maintenance temozolomide (TMZ) after definitive therapy for locally advanced non-small-cell lung cancer (NSCLC) could decrease the incidence of...” PMID 25069747 ↗ Jun 2014 “Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day...” NCT04881032 ↗ “PURPOSE: To determine the response rate (RR) of neuroblastoma (NB) in children to temozolomide (TMZ), and evaluate the duration of response and tolerance of the drug in this...” PMID 17114659 ↗ Nov 2006 “Temozolomide (TMZ), an oral DNA-alkylating agent routinely used in the therapy of glioblastoma multiforme, is active in patients with primary CNS lymphoma but the response...” PMID 24178621 ↗ Oct 2013 “combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse” NCT04910022 ↗ “upfront therapy with bevacizumab (BV), irinotecan (CPT-11), and temozolomide (TMZ) prior to chemoradiation in patients with unresectable, subtotally resected, and/or multifocal GBM.” PMID 26025933 ↗ May 2015 “Preclinical studies suggest that high dose macitentan, an oral dual endothelin receptor antagonist, enhances the cytotoxic effects of temozolomide (TMZ) in GBM, improving survival.” PMID 34693288 ↗ Oct 2021 “Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.” NCT03746080 ↗ “An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with temozolomide (TMZ) followed by adjuvant TMZ was conducted by the Children's Oncology Group.” PMID 21345842 ↗ Feb 2011 “The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.” NCT06161974 ↗ “EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.” PMID 19945857 ↗ Nov 2009 “This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (NIR) with temozolomide (TMZ; arm 1) or irinotecan (IRN; arm 2) in patients with pretreated ES.” PMID 33289920 ↗ Dec 2020 “SI-053 is a novel powder formulation containing temozolomide (TMZ), an alkylating chemotherapy agent, in an excipient which forms a viscous gel upon reconstitution in water.” NCT04967690 ↗ “patients with BM from NSCLC were randomly assigned to 30Gy WBRT with either concomitant gefitinib (GFT) 250mg/day continuously or temozolomide (TMZ) 75mg/m(2) for 21/28days.” PMID 22093943 ↗ Nov 2011 “Temozolomide (TMZ) is the chemotherapy drug approved by the FDA to increase survival in glioblastoma (GBM) patients beyond surgical resection and radiation therapy alone.” NCT02781792 ↗ “PURPOSE: This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM).” PMID 22160854 ↗ Dec 2011 “Patients were randomized 2:1:1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2).” PMID 27370396 ↗ Jul 2016 “The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT)” NCT02340156 ↗ “Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.” NCT03082846 ↗ “Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma” NCT00553150 ↗ “This Phase 1 expansion cohort of letrozole 15mg administered in combination with 50 mg/m2 metronomic temozolomide (TMZ) in patients with high grade gliomas.” NCT03122197 ↗ “Current standard of care for glioblastoma (GBM) includes concurrent chemoradiation and maintenance temozolomide (TMZ) with Tumor Treating Fields (TTFields).” PMID 36355259 ↗ Nov 2022 “Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ.” NCT02772094 ↗ “The alkylating agent Temozolomide (TMZ) is an oral chemotherapy drug that damages DNA by adding methyl groups to the O6- and N7- positions of guanine” NCT05128734 ↗ “Temozolomide (TMZ), a new alkylating and methylating agent, has demonstrated high response rates in patients with recurrent anaplastic astrocytoma.” PMID 12829671 ↗ Jul 2003 “Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.” PMID 23357973 ↗ Aug 2014 “The chemotherapy that is being used in this study is called temozolomide (TMZ) which is the standard-of-care used to treat glioblastoma patients.” NCT05664243 ↗ “Recurrence is inevitable, largely due to O6 methylguanine DNA methyltransferase (MGMT) that renders the tumors resistant to temozolomide (TMZ).” PMID 32578964 ↗ Jun 2020 “This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma.” PMID 20042969 ↗ Dec 2010 “Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study.” NCT03234595 ↗ “initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade glioma (LGG) patients.” PMID 29571083 ↗ Mar 2018 “methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ.” PMID 27022122 ↗ Mar 2016 “Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG).” PMID 15073861 ↗ Apr 2004 “This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas.” NCT03930771 ↗ “The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective.” NCT03396575 ↗ “Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles.” NCT02193347 ↗ “Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma.” PMID 12649108 ↗ Apr 2003 “Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily from Weeks 1 to 6.” NCT00689221 ↗ “Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).” NCT03491683 ↗ “Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles.” NCT02898012 ↗ “Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT).” NCT00080938 ↗ “Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma” NCT00304031 ↗ “temozolomide (TMZ) in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)” PMID 24764124 ↗ Apr 2014 “in combination with Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors” NCT01618136 ↗ “Temozolomide (TMZ, Temodar®) is an orally administered alkylating agent with activity against malignant gliomas” NCT00704080 ↗ “whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM)” NCT02385136 ↗ “Temozolomide (TMZ) 75 milligram per square meter \[mg/m\^2\] will be administered intravenously once daily” NCT00813943 ↗ “Temozolomide (TMZ), an orally administered drug, was shown to be efficient in DLGG, with a good tolerance” NCT03257618 ↗ “Temozolomide(TMZ) will be administered at 75 mg/m\^2 concomitant to radiotherapy(RT) and NovoTTF-200A.” NCT03780569 ↗ “when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients.” PMID 18359865 ↗ Mar 2008 “we investigated the efficacy and safety of WBRT combined with temozolomide (TMZ) in this population.” PMID 25355723 ↗ Oct 2014 “Part 1: dose-escalation phase to determine MTD of TAS-102 in combination with Temozolomide (TMZ).” NCT02943733 ↗ “Arm A, Cohort 2: nab-sirolimus + temozolomide (TMZ) in patients with recurrent high grade glioma” NCT03463265 ↗ “daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)” NCT04614493 ↗ “For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.” NCT03224104 ↗ “combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone” NCT00076856 ↗ “Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG).” PMID 20855843 ↗ Sep 2010 “concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period” NCT06418113 ↗ “Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles.” NCT04195139 ↗ “Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks.” NCT03535350 ↗ “6 cycles of 28 days with L19TNF (D1, D3, D5) and temozolomide chemotherapy TMZ (D1-5).” NCT07120984 ↗ “Temozolomide (TMZ) is an oral alkylating agent that crosses blood-brain barrier (BBB).” NCT02133677 ↗ “Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine” PMID 25924937 ↗ Apr 2015 “Temozolomide (TMZ): 150-200 mg/m2, po. Q4W, d1-5, for a total of 6 cycles” NCT07047066 ↗ “Temozolomide (TMZ, Temodar®) is an orally administered alkylating agent.” NCT00960492 ↗ “radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days” PMID 32064499 ↗ Aug 2020 “RT concurrent with TMZ (75 mg/m2/d, 7 d/week) followed by adjuvant TMZ” PMID 34902368 ↗ Dec 2021 “temozolomide (TMZ), a DNA alkylating agent used to treat brain tumors.” PMID 32652442 ↗ Jul 2020 “Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent.” NCT05858177 ↗ “Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent.” NCT05885386 ↗ “Temozolomide (TMZ) will be administered on day 1 of radiation therapy” NCT03018288 ↗ “Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days” NCT01402063 ↗ “Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os)” NCT03663725 ↗ “dasatinib with radiation and temozolomide (TMZ) for glioblastoma.” PMID 40579995 ↗ Oct 2025 “Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle.” NCT01567202 ↗ “temozolomide (TMZ) combined with orelabrutinib and selinexor” NCT07191431 ↗ “Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days.” NCT03299309 ↗ “O6-benzylguanine (BG) and dose-escalated temozolomide (TMZ)” NCT01269424 ↗ “standard temozolomide (TMZ) has, at best, limited efficacy.” PMID 26976423 ↗ Mar 2016 “temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles” NCT01310868 ↗ “with or without temozolomide (TMZ), in patients with GBM.” PMID 34787778 ↗ Nov 2021 “Temozolomide (TMZ) is a drug used to treat brain tumors.” NCT02942264 ↗ “temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks” NCT00267592 ↗ “combination temozolomide (TMZ) and veliparib (ABT-888)” PMID 26449224 ↗ Oct 2015 “During RT, patients will receive Temozolomide (TMZ).” NCT03529448 ↗ “Radiotherapy in combination with Temozolomide (TMZ)” NCT02799238 ↗ “Lanreotide autogel (LAN) and temozolomide (TMZ) are” PMID 36044870 ↗ Aug 2022 “Temozolomide（TMZ） injection or oral administration” NCT06330337 ↗ “peri-radiation therapy temozolomide (TMZ)” PMID 24380758 ↗ Oct 2013 “Temozolomide (TMZ) daily for 21 days” NCT04765514 ↗ “combination with Temozolomide (TMZ)” NCT04851834 ↗ “Temozolomide (TMZ) and Bevacizumab” NCT00626405 ↗ “lymphodepleting temozolomide (TMZ)” PMID 22383993 ↗ Feb 2012 “upfront RT and temozolomide (TMZ)” NCT06072586 ↗ “receive RT and temozolomide (TMZ)” NCT06816927 ↗ “radiation and temozolomide (TMZ)” PMID 38263486 ↗ Jan 2024 “concomitant temozolomide (TMZ)” NCT00887146 ↗ “Drug: Temozolomide (TMZ)” NCT01356290 ↗ “Drug: Temozolomide (TMZ)” NCT06478212 ↗ “Drug: Temozolomide (TMZ)” NCT04421378 ↗ “Drug: Temozolomide (TMZ)” NCT07605364 ↗ “Drug: Temozolomide (TMZ)” NCT01390948 ↗ “temozolomide (TMZ)” NCT04817254 ↗ “Temozolomide (TMZ)” NCT04961515 ↗ “Temozolomide (TMZ)” NCT07389278 ↗ “temozolomide (TMZ)” NCT03832621 ↗ “Temozolomide (TMZ)” NCT07334301 ↗ “Temozolomide (TMZ)” NCT06353360 ↗ “Temozolomide (TMZ)” NCT02231762 ↗ “Temozolomide (TMZ)” NCT03405792 ↗ “Temozolomide (TMZ)” NCT04388475 ↗ “temozolomide (TMZ)” NCT01127178 ↗ “Temozolomide (TMZ)” NCT01587144 ↗ “Temozolomide (TMZ)” NCT00525031 ↗ “temozolomide (TMZ)” NCT03914742 ↗ “Temozolomide (TMZ)” NCT07562971 ↗ “Temozolomide (TMZ)” NCT06208657 ↗ “Temozolomide (TMZ)” NCT04121455 ↗ “Temozolomide (TMZ)” NCT07243470 ↗ “Temozolomide (TMZ)” NCT00395070 ↗ “TMZ (Temozolomide)” NCT00895960 ↗ “Temozolomide (TMZ)” NCT03212742 ↗ “Temozolomide (TMZ)” NCT05417594 ↗ “Temozolomide (TMZ)” NCT03749187 ↗ “Temozolomide (TMZ)” NCT05843253 ↗ “Temozolomide (TMZ)” NCT06760117 ↗ “Temozolomide (TMZ)” NCT07365280 ↗ “Temozolomide (TMZ)” NCT07599371 ↗ “Temozolomide (TMZ)” NCT04457284 ↗ “Temozolomide (TMZ)” NCT01506609 ↗ “Temozolomide (TMZ)” NCT06721689 ↗ “TMZ(temozolomide)” NCT00974987 ↗ “TMZ” NCT06419946 ↗ |
| Action | Inhibit | “Temozolomide's inhibition of AGT” PMID 20511167 ↗ Jun 2010 |
| Modality | Small molecule | “Temozolomide is an alkylating agent” PMID 18626572 ↗ Jul 2008 |
| Route | Oral | “administered orally” PMID 12763216 ↗ Jun 2003 |
| Target | AGT | “Temozolomide's inhibition of AGT may sensitize leukemia cells” PMID 20511167 ↗ Jun 2010 |